Prasinezumab

The multifaceted nature of Parkinson’s disease: potential treatment targets 1:25
The multifaceted nature of Parkinson’s disease: potential treatment targets
Gennaro Pagano • 29 Aug 2023
PADOVA study: prasinezumab in patients with early Parkinson’s disease 2:53
PADOVA study: prasinezumab in patients with early Parkinson’s disease
Tania Nikolcheva • 29 Aug 2023
Update on the PASADENA trial of prasinezumab for Parkinson’s disease 1:57
Update on the PASADENA trial of prasinezumab for Parkinson’s disease
Gennaro Pagano • 29 Aug 2023
Parkinson’s disease: updates in the disease-modifying space 1:36
Parkinson’s disease: updates in the disease-modifying space
Angelo Antonini • 1 Jul 2023
What is the future of immunotherapy in Parkinson’s disease? 2:03
What is the future of immunotherapy in Parkinson’s disease?
Gennaro Pagano • 5 Apr 2023
Assessing the efficacy of antibodies targeting α-synuclein 1:38
Assessing the efficacy of antibodies targeting α-synuclein
Fabrizio Stocchi • 16 Oct 2022
PADOVA trial: prasinezumab in early Parkinson’s disease 1:34
PADOVA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease 1:43
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Key clinical trials of disease modifying therapies in Parkinson’s disease 2:12
Key clinical trials of disease modifying therapies in Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
PASADENA trial: prasinezumab in early Parkinson’s disease 1:24
PASADENA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease 1:29
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Learnings from the PASADENA trial in Parkinson’s disease 1:49
Learnings from the PASADENA trial in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
The field of Parkinson’s disease research is expanding 1:24
The field of Parkinson’s disease research is expanding
Gennaro Pagano • 10 Mar 2021
The content of VJNeurology is intended for healthcare professionals